May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
EphrinA1 inhibits VEGF–induced intracellular signaling and suppresses retinal neovascularization and blood–retinal barrier breakdown.
Author Affiliations & Notes
  • T. Ojima
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • H. Takagi
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • K. Suzuma
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • I. Suzuma
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • H. Oh
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • H. Ohashi
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • D. Watanabe
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • E. Suganami
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • Y. Honda
    Ophthalmology & Visual Sciences, Kyoto University, Kyoto, Japan
  • Footnotes
    Commercial Relationships  T. Ojima, None; H. Takagi, None; K. Suzuma, None; I. Suzuma, None; H. Oh, None; H. Ohashi, None; D. Watanabe, None; E. Suganami, None; Y. Honda, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 3582. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Ojima, H. Takagi, K. Suzuma, I. Suzuma, H. Oh, H. Ohashi, D. Watanabe, E. Suganami, Y. Honda; EphrinA1 inhibits VEGF–induced intracellular signaling and suppresses retinal neovascularization and blood–retinal barrier breakdown. . Invest. Ophthalmol. Vis. Sci. 2004;45(13):3582.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We previously presented that ephrinA1 suppressed VEGF–induced proliferation and intracellular signaling cascades including protein kinase C (PKC)–extracellular signal–regulated kinase (ERK) pathway and Akt in cultured retinal vascular endothelial cells. In the present study, we further investigated this mechanism and examined the effect of ephrinA1 on retinal neovascularization and vascular permeability in animal models. Methods: The effect of ephrinA1 on VEGF–induced phosphorylation of intracellular signaling molecules was investigated by immunoprecipitation and Western blot analysis. The involvement of phosphatase in this mechanism was also investigated using dominant negative SHP1 and SHP2 adenoviruses. The effect of intraocular injection of ephrinA1 on retinal neovascularization and vascular permeability was investigated in ROP (retinopathy of prematurity) mouse model and in a rat model using Evans–blue method, respectively. Results: EphrinA1 inhibited VEGF–induced migration and tube formation activity of BRECs (bovine retinal microvascular endothelial cells) by 50.0±7.2% and 67.3±1.0%, respectively. Western blot analysis showed that ephrinA1 inhibited VEGF–induced phosphorylation of KDR/Flk–1 receptors by 63.8±16.5% followed by suppression of PLCγ–PKC–ERK pathway and Akt. SHP1DN and SHP2DN adenoviruses had no effect on this suppression by ephrinA1. Intraocular injection of ephrinA1 suppressed retinal neovascularization in ROP mouse by 36.0±14.9%. Intraocular injection of VEGF increased blood–retinal barrier breakdown by 3.3±0.6 fold in a rat model, which was suppressed by co–injection with ephrinA1 by 46.0±10.0%. Conclusions:It was suggested that ephrinA1 inhibited VEGF–induced intracellular signaling through KDR/Flk–1 receptor inhibition. Suppression of in vivo retinal neovascularization and vascular permeability by ephrinA1 indicates the therapeutic possibility of ephrinA1 for retinal neovascularization and vasopermeability abnormalities in ischemic retinal diseases including diabetic retinopathy.

Keywords: hypoxia • growth factors/growth factor receptors • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×